News Can GLP-1 drugs help tackle addiction? New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.
News Novo Nordisk plans €432m investment in Irish GLP-1 plant Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.
News Lilly says orforglipron tops Novo pill in diabetes trial Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.
News Novo Nordisk beefs up in oral obesity drugs with Vivtex deal Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News NICE backs changes to NHS' diabetes care pathway New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.
News Novo Nordisk's CagriSema tops Ozempic in diabetes trial Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
